CN Patent

CN115671109A — 磷酸西格列汀的用途

Assigned to Liaoning Kangchen Nuoxin Pharmaceutical Technology Co ltd · Expires 2023-02-03 · 3y expired

What this patent protects

本发明涉及生物医药技术领域，具体涉及磷酸西格列汀的用途，包括磷酸西格列汀在制备治疗过敏性皮肤病药物中的应用，属于医药技术领域。本发明通过研究发现，磷酸西格列汀可用于治疗免疫球蛋白E(IgE)介导的过敏性皮肤病，为过敏性皮肤病的治疗提供了一种新的思路及方案。

USPTO Abstract

本发明涉及生物医药技术领域，具体涉及磷酸西格列汀的用途，包括磷酸西格列汀在制备治疗过敏性皮肤病药物中的应用，属于医药技术领域。本发明通过研究发现，磷酸西格列汀可用于治疗免疫球蛋白E(IgE)介导的过敏性皮肤病，为过敏性皮肤病的治疗提供了一种新的思路及方案。

Drugs covered by this patent

Patent Metadata

Patent number
CN115671109A
Jurisdiction
CN
Classification
—
Expires
2023-02-03
Drug substance claim
No
Drug product claim
No
Assignee
Liaoning Kangchen Nuoxin Pharmaceutical Technology Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.